ADC Therapeutics

Pharma BioPharma,

ADC Therapeutics strikes a $325M royalty deal to fuel its cancer drug strategy

The royalty agreement with HealthCare Royalty Partners will support ADC Therapeutics’ plans to commercialize its newly approved cancer drug and develop the next one in its pipeline. The biotech’s drug Zynlonta is the first of its type approved by the FDA as a treatment for diffuse large cell B-cell lymphoma

By Frank Vinluan

BioPharma, Pharma

FDA approves ADC Therapeutics antibody drug conjugate in B-cell lymphoma

With FDA approval of Zynlonta, ADC Therapeutics can offer patients who have diffuse large B-cell lymphoma an option if CAR-T therapy doesn’t work. Additional clinical trials are underway that could expand use of the antibody drug conjugate to more cancer patients.

By Frank Vinluan

The Healthcare Payments Industry Faces a Perception Challenge

Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.

By Lisa Brooks, Vice President, Healthcare Partnerships

Closing the Quality-Affordability Gap in Workplace Mental Health

In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.

By Stephanie Baum

Top 7 Modern AI-Powered EAP Providers for Global Workforces in 2026

Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.

By Tiffany Cabasso, Operations Director, Kyan Health | Psychologist, FSP